HiberCell is a clinical-stage pharmaceutical company committed to developing novel therapeutics that address the relapse and metastasis of cancers.

At this time, HiberCell does not offer an expanded access program and is not accepting single patient expanded access requests for its investigational products. Our current focus is on completing development programs to obtain the needed safety and efficacy data for regulatory approval as quickly and as safely as possible. As our investigational product(s) advance in development, we will review our expanded access policy and may make updates to it.

Information about our clinical trials, including eligibility criteria and locations, is available at www.clinicaltrials.gov and on the HiberCell website hibercell.com. Questions about HiberCell’s investigational products and clinical trials be addressed to contact@hibercell.com.